N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders

N-Acetyl Cysteine add-on to Antidepressant Medication in Therapy Refractory Major Depressive Disorder Patients With Increased Inflammatory Activity

The aim of this study is to evaluate the efficacy of N-acetylcysteine (NAC) add-on to antidepressant medication in treating patients who do not relieve during standard antidepressant treatment for 6 weeks at least. Meanwhile, secondary outcomes will include changes in some biomarkers and on specifically local brain activity (functional Magnetic Resonance Imaging, fMRI) and white matter integrity (Diffusion Tensor Imaging, DTI). The hypothesis of this study is that NAC has positive effects on refractory major depressive disorder patients with increased inflammatory activity.

Study Overview

• Status: Recruiting
• Conditions: Major Depressive Disorders
• Intervention / Treatment: Drug: N-acetylcysteine; Drug: placebo comparator of N-acetylcysteine

Detailed Description

It's a double-blind randomised placebo controlled antidepressant augmentation study with 12-week treatment and 8-week follow up. Its purpose is to investigate antidepressant efficacy and safety of NAC in patients with treatment resistant depression (TRD) defined as insufficient response to 1 or more antidepressants given for at least 6 weeks and in an adequate dose, displaying increased peripheral inflammatory activity and moderate to severe depression. Apart from studying the effects of NAC on depression severity, the secondary outcomes are to examine a range of biomarkers related to potentially important underlying mechanisms such as oxidative stress and inflammatory activity and to evaluate the effects on brain functioning (fMRI) and on white matter integrity (DTI). Scale assessments are performed in the week preceding initiation of treatment, during the treatment period, at the end of the treatment period and at 8-week follow up. Neuro-imaging is performed before the treatment starts and in week 12, before the study medication is terminated. Collection of blood and morning urine only takes place at three time points, in the week preceding initiation of treatment, closely before tapering off the study medication and at the end of 8-week follow up. This study is hoped to show that NAC perform positive effects on those aspects mentioned above.

• Study Type: Interventional
• Enrollment (Anticipated): 200
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Chenghao Yang, Master; Phone Number: 086 13752539531; Email: yts83420@163.com

Study Locations

• China
  • Tianjin
    • Tianjin, Tianjin, China, 300222
      • Recruiting
      • Tianjin Anding Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• a current episode of MDD diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) diagnosed with SCID
• an age between 18 and 65 years
• a total score of HAMD-17 ≥ 17
• a CRP level between 0.85 and 10 mg/L (The CRP range is based on literature values for mild to moderate chronic inflammation, while values > 10 mg/L point at acute inflammation. A pilot study at the Tianjin Hospital (n=62) indicated that approximately one third of all patients with MDD will have CRP values within this range). insufficient response to 1 or more antidepressants given for at least 6 weeks and in an adequate dose during the current episode
• stable dose of the current antidepressant drug for at least 2 weeks prior to initiation of the study
• Patients are allowed to use benzodiazepines (BZD) to relieve anxiety during the first phase of antidepressant treatment (Anding Hospital protocol). Benzodiazepines may also be prescribed because of sleeping problems during the trial. BZD use will be recorded at all assessments during the trial and after follow-up.
• Patients are compliant with treatment according to the judgement of the treating clinician.
• Female subjects will be eligible to participate in the study if they are of non-childbearing potential or of child-bearing potential and willing to practice appropriate birth control methods during the study. Clinical patients always get a pregnancy test before start of treatment.
• Participant or guardian has to sign informed consent. The patients' guardians will sign the informed consent on behalf of the participants when the capacity of participants to consent is compromised.

Exclusion Criteria:

• A history of manic episode
• Use of mood stabilizer
• Use of antipsychotic medication with more than half of the maximum dosage suggested in the instruction
• History of substance abuse or dependence
• An allergic reaction to NAC or any component of the preparation
• Severe somatic diseases that might interfere with regular antidepressant treatment including conditions such as kidney and liver failure, uncontrolled hypertension, cardiovascular, cerebrovascular and pulmonary disease, thyroid disease, diabetes, epilepsy and asthma.
• Use of anti-inflammatory medication for longer than 7 days in the last two months preceding the trial
• Use of immunosuppressive medication such as oral steroid hormones
• History of chronic infection, such as Tuberculosis, AIDS, hepatitis
• CRP value > 10 mg/L
• Women in pregnancy or lactation period

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NAC group; Participants of "NAC group" receive 1000 mg NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)	Drug: N-acetylcysteine; Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.; Other Names: YiWeiShi
Placebo Comparator: Placebo group; Participants of "Placebo group" receive placebo matched with NAC twice daily for 12 weeks as add-on to either a selective serotonin reuptake inhibitor (SSRI) or a serotonin and noradrenalin reuptake inhibitor (SNRI)	Drug: placebo comparator of N-acetylcysteine; Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The change from baseline Hamilton Depression Rating Scale (HAMD)-17 items at week2,4,6,8,10,and 12.	The main objective is to investigate whether daily oral NAC administration in addition to regular treatment with an antidepressant will alleviate the severity of MDD symptoms as measured with the HAMD-17 after 12 weeks of treatment compared to placebo addition, and we also look at other time points, such as week 2,4,6,8,and 10.	baseline, Week 2,4,6,8,10, and 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The change from baseline HAMD-17 items at week14,16,18,and 20.	We also look at whether daily oral NAC treatment will still have measurable effects on HAMD-17 score at 8 weeks follow-up after discontinuation of NAC treatment.	baseline, Week 14,16,18,and 20.
The effects of augmentation treatment with NAC on scores in Beck Anxiety Inventory (BAI)		baseline, Week 4,8,12,16,and 20.
The effects of augmentation treatment with NAC on scores in Inventory of Depressive Symptoms-Self-Rated (IDS-SR)		baseline, Week 4,8,12,16,and 20.
The effects of augmentation treatment with NAC on scores in WHO Disability Assessment Schedule Ⅱ (WHODAS-Ⅱ)		baseline, Week 4,8,12,16,and 20.
The effects of augmentation treatment with NAC on scores in Montreal Cognitive Assessment (MoCA)		baseline, Week 4,8,12,16,and 20.
The effects of augmentation treatment with NAC on local brain activity (fMRI and DTI)		baseline, the end of week 12.
The effects of augmentation treatment with NAC on a range of biomarkers representing the alleged underlying pathophysiological mechanisms	biomarkers associated with inflammation, oxidative stress, and neurogenesis in sample of serum and urine.	baseline, the end of the week 12 and 20
Assessments the side effects measured with Checklist of 52 Somatic Items (CSI)		baseline, Week 4,8,12,16,and 20.

Collaborators and Investigators

• Sponsor: Tianjin Anding Hospital

Publications and helpful links

General Publications

• Yang C, Bosker FJ, Li J, Schoevers RA. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial. BMC Psychiatry. 2018 Sep 4;18(1):279. doi: 10.1186/s12888-018-1845-1.

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2015
• Primary Completion (Anticipated): July 1, 2023
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: November 12, 2016
• First Submitted That Met QC Criteria: November 20, 2016
• First Posted (Estimate): November 23, 2016

Study Record Updates

• Last Update Posted (Actual): September 22, 2022
• Last Update Submitted That Met QC Criteria: September 21, 2022
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Keywords: oxidative stress; inflammation mediators; N-Acetyl Cysteine; treatment resistant depression; brain imaging
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Depression; Depressive Disorder; Depressive Disorder, Major; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Protective Agents; Respiratory System Agents; Antioxidants; Antidotes; Free Radical Scavengers; Expectorants; Acetylcysteine; N-monoacetylcystine
• Other Study ID Numbers: NAC-2015-TJAH

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided